Understanding Eli Lilly's $3.2B Investment in a Struggling Cancer Startup
Eli Lilly's decision to invest $3.2 billion in a struggling biotech startup raises questions about the potential the pharma giant sees in the company. Insights from Bryan Roberts may shed light on this move.